Eli Lilly monoclonal antibody drug trial paused over safety concerns

(Natural News) Eli Lilly & Company are halting the enrollment of participants in a clinical trial of its antibody treatment for the Wuhan coronavirus (COVID-19) due to safety concerns. According to company spokeswoman Molly McCully, an independent data and safety monitoring board (DSMB) had recommended pausing enrollment in the U.S. government-sponsored trials. Lilly, however, did not say...